Abstract:Abstract Mutations of PINK1 cause early-onset Parkinson’s disease (PD) with selective neurodegeneration in humans. However,current PINK1 knockout mouse and pig models are unable to recapitulate the typical neurodegenerative phenotypes observed in PD patients, indicating that it is essential to generate PINK1 disease models in non-human primates (NHPs) that are highly close to humans, to investigate the unique function of PINK1 in primate brains. Paired single guide RNA (sgRNA)/Cas9-D10A nickases and truncated sgRNA/Cas9, both enabling the reduction of the off-target effect without apparently compromising the on-target editing, are two optimized strategies in applying the CRISPR/Cas9 system to establish disease animal models. Here, we combined the two strategies and injected Cas9-D10A mRNA and two truncated sgRNAs into one-cell-stage cynomolgus zygotes to target PINK1 gene. We show precise and efficient gene editing of the target site in the three new born cynomolgus monkeys. The frame shift mutations of PINK1 in mutant fibroblasts leaded to the reduction of the mRNA, However, western-blot and immunofluorescencestaining confirmed the PINK1 proteinlevels werecomparable to that in the wild-type fibroblasts. We further reprogramed mutant fibroblast into induced pluripotent stem cells (iPSCs) and they show similar ability of differentiation into dopamine (DA) neurons. Taken together, our results showed that coinjection of Cas9-D10A nickase mRNA and sgRNA into one-cell-stage cynomolgus embryos enable the generation of human disease models in NHPs and the target editing by paired truncated sgRNA/Cas9-D10A in PINK1 gene exon 2 did not impact the protein expression.

CRISPR/Cas9-mediated genome editing in nonhuman primates

Trio deep-sequencing does not reveal unexpected mutations in Cas9-edited monkeys

Trio Deep-Sequencing Does Not Reveal Unexpected Off-Target and On-Target Mutations in Cas9-edited Rhesus Monkeys

[Applications of ZFN, TALEN and CRISPR/Cas9 Techniques in Disease Modeling and Gene Therapy].

Paving the Road for Biomedicine: Genome Editing and Stem Cells in Primates

CRISPR/Cas9 genome editing to create nonhuman primate models for studying stem cell therapies for HIV infection

Opportunities and limitations of genetically modified nonhuman primate models for neuroscience research

CRISPR/Cas9 PIG -A gene editing in nonhuman primate model demonstrates no intrinsic clonal expansion of PNH HSPCs.

Generation of in situ CRISPR-mediated primary and metastatic cancer from monkey liver

Opportunities and challenges in modeling human brain disorders in transgenic primates

Targeted Genome Editing in Primate Embryos

Embryo-Engineered Nonhuman Primate Models: Progress and Gap to Translational Medicine

PINK1 gene mutation by pair truncated sgRNA/Cas9-D10A in cynomolgus monkeys

Application of CRISPR/Cas9 System in Establishing Large Animal Models

Mutating PINK1 gene by paired truncated sgRNA/Cas9-D10A in Cynomolgus Monkey

Genetically Modified Non-Human Primate Models for Research on Neurodegenerative Diseases.

Advances in optogenetic and chemogenetic methods to study brain circuits in non-human primates

Development and application of CRISPR/Cas9 technologies in genomic editing.

CRISPR-engineered genome editing for the next generation neurological disease modeling

A piggyBac-based platform for genome editing and clonal rhesus macaque iPSC line derivation

CRISPR/Cas9: Implications for Modeling and Therapy of Neurodegenerative Diseases